CEBPB and colitis: In summary, this study shows that inhibition of super-enhancer–driven CEBPB/PCK1 and CEBPB/EFNA1 signaling pathways can reduce LPS-induced barrier dysfunction in vitro and improve DSS-induced experimental colitis in vivo.